flow trial semaglutide ppt Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk FLOW: Semaglutide Scores Big in

Bechlioulis A, Markozannes G, Chionidi I, et al

Many see improvement by month 6 and more obvious volume recovery by month 912, assuming nutrition and health stabilize

Future perspectives in terms of nephro-protection in lupus nephritis Finerenone Novel MRA, like finerenone, are known to block MR-mediated sodium reabsorption and MR overactivation with additionally demonstrated anti-inflammatory and anti-fibrotic effects ( SGLT2i Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently been demonstrated to exert profound cardio and nephroprotection in large cardiovascular outcome trials ( via a glucose-independent hemodynamic mechanism

Providers who stay informed about regulatory updates, insurance trends, and patient education needs will be better positioned to navigate this evolving treatment environment